Work

Abstract PO4-17-02: A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs23-po4-17-02

Authors: Joyce O'Shaughnessy, Reva Basho, Maryam Lustberg, Gary H Lyman, Manoj Prahladan, Gareth D. James, Della Varghese, Flavia Lujan, Hans Tesch

Institutions: Baylor University Medical Center, Ellison Medical Institute, Yale Cancer Center, Fred Hutch Cancer Center, AstraZeneca (United Kingdom)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396591296

Cites:

Cited by:

Related to: 10